The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: A target for multiple sclerosis therapy?

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 5, 2012, Pages 451-462

  Lee, De Hyung ^a   Linker, Ralf A ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Demyelination; Experimental autoimmune encephalomyelitis; MOG specific antibodies; Multiple sclerosis; Myelin oligodendrocyte glycoprotein

Indexed keywords

MYELIN OLIGODENDROCYTE GLYCOPROTEIN; RITUXIMAB;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNITY; B LYMPHOCYTE; CELLULAR IMMUNITY; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOPATHOGENESIS; MULTIPLE SCLEROSIS; NONHUMAN; PLASMAPHERESIS; PROTEIN FUNCTION; REVIEW; T CELL DEPLETION; T LYMPHOCYTE;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; B-LYMPHOCYTES; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; T-LYMPHOCYTES;

EID: 84860261833     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.677438     Document Type: Review

References (121)

1. Lassmann H, Suchanek G, Ozawa K. Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis. Ann Neurol 1994;36(Suppl):S42-6
2. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285
3. Quarles RH. Glycoproteins of myelin sheaths. J Mol Neurosci 1997;8:1-12
4. Seil FJ, Falk GA, Kies MW, et al. The in vitro demyelinating activity of sera from guinea pigs sensitized with whole CNS and with purified encephalitogen. Exp Neurol 1968;22:545-555
5. Raine CS, Hummelgard A, Swanson E, et al. Multiple sclerosis: Serum-induced demyelination in vitro. A light and electron microscope study. J Neurol Sci 1973;20:127-148
6. Lebar R, Boutry JM, Robineaux R, et al. Induction and prevention of allergic experimental encephalomyelitis in guinea pigs. Relationship with in vitro induced injuries and with class and specificity of the autoantibodies produced. C R Acad Sci Hebd Seances Acad Sci D 1973;276:1635-1638
7. Linington C, Izumo S, Suzuki M, et al. A permanent rat T cell line that mediates experimental allergic neuritis in the Lewis rat in vivo. J Immunol 1984;133:1946-1950
8. Gardinier MV, Amiguet P, Linington C, et al. Myelin/oligodendrocyte glycoprotein is a unique member of the immunoglobulin superfamily. J Neurosci Res 1992;33:177-187
9. Hilton AA, Slavin AJ, Hilton DJ, et al. Characterization of cDNA and genomic clones encoding human myelin oligodendrocyte glycoprotein. J Neurochem 1995;65:309-318
10. Pham-Dinh D, Mattei MG, Nussbaum JL, et al. Myelin/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex. Proc. Natl. Acad. Sci. USA 1993;90:7990-7994
11. Genain CP, Nguyen MH, Letvin NL, et al. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate 1. J Clin Invest 1995;96:2966-2974
12. Kerlero De RN, Honegger P, Lassmann H, et al. Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin/oligodendrocyte glycoprotein. J Neurochem 1990;55:583-587
13. Linington C, Lassmann H. Antibody responses in chronic relapsing experimental allergic encephalomyelitis: Correlation of serum demyelinating activity with antibody titre to the myelin/oligodendrocyte glycoprotein (MOG). J Neuroimmunol 1987;17:61-69
14. Linington C, Bradl M, Lassmann H, et al. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988;130:443-454
15. Linington C, Engelhardt B, Kapocs G, et al. Induction of persistently demyelinated lesions in the rat following the repeated adoptive transfer of encephalitogenic T cells and demyelinating antibody. J Neuroimmunol 1992;40:219-224
16. Schluesener HJ, Sobel RA, Linington C, et al. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 1987;139:4016-4021
17. Villoslada P, Shih A, Shao L, et al. Autoreactivity to myelin antigens: Myelin/oligodendrocyte glycoprotein is a prevalent autoantigen 1. J Neuroimmunol 1999;99:36-43
18. Kerlero De RN, Milo R, Lees MB, et al. Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest 1993;92:2602-2608
19. Lindert RB, Haase CG, Brehm U, et al. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain 1999;122(Pt 11):2089-2100
20. Genain CP, Cannella B, Hauser SL, et al. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999;5:170-175
21. Raine CS, Cannella B, Hauser SL, et al. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: A case for antigen-specific antibody mediation. Ann Neurol 1999;46:144-160
22. Slavin AJ, Johns TG, Orian JM, et al. Regulation of myelin oligodendrocyte glycoprotein in different species throughout development. Dev Neurosci 1997;19:69-78
23. Gunn C, Suckling AJ, Linington C. Identification of a common idiotype on myelin oligodendrocyte glycoprotein-specific autoantibodies in chronic relapsing experimental allergic encephalomyelitis. J Neuroimmunol 1989;23:101-108
24. Lassmann H, Brunner C, Bradl M, et al. Experimental allergic encephalomyelitis: The balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions. Acta Neuropathol 1988;75:566-576
25. Hjelmstrom P, Juedes AE, Fjell J, et al. B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization. J Immunol 1998;161:4480-4483
26. Hjelmstrom P, Penzotti JE, Henne RM, et al. A molecular model of myelin oligodendrocyte glycoprotein. J Neurochem 1998;71:1742-1749
27. Dyer CAMatthieu JM. Antibodies to myelin/oligodendrocyte-specific protein and myelin/oligodendrocyte glycoprotein signal distinct changes in the organization of cultured oligodendroglial membrane sheets. J Neurochem 1994;62:777-787
28. Johns TG, Bernard CC. The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem 1999;72:1-9
29. Matthieu JM, Comte V, Tosic M, et al. Myelin gene expression during demyelination and remyelination in aggregating brain cell cultures. J Neuroimmunol 1992;40:231-234
30. Kroepfl JF, Viise LR, Charron AJ, et al. Investigation of myelin/oligodendrocyte glycoprotein membrane topology. J Neurochem 1996;67:2219-2222
31. Della GB, Pham-Dinh D, Roussel G, et al. Membrane topology of the myelin/oligodendrocyte glycoprotein. Eur J Biochem 1998;258:478-484
32. Pribyl TM, Campagnoni CW, Kampf K, et al. Expression of the myelin basic protein gene locus in neurons and oligodendrocytes in the human fetal central nervous system. J Comp Neurol 1996;374:342-353
33. Burger D, Steck AJ, Bernard CC, et al. Human myelin/oligodendrocyte glycoprotein: A new member of the L2/HNK-1 family. J Neurochem 1993;61:1822-1827
34. Schachner M, Martini R, Hall H, et al. Functions of the L2/HNK-1 carbohydrate in the nervous system. Prog Brain Res 1995;105:183-188
35. Scolding NJ, Frith S, Linington C, et al. Myelin-oligodendrocyte glycoprotein (MOG) is a surface marker of oligodendrocyte maturation. J Neuroimmunol 1989;22:169-176
36. Matthieu JM, Amiguet P. Myelin/oligodendrocyte glycoprotein expression during development in normal and myelin-deficient mice. Dev Neurosci 1990;12:293-302
37. Pfeiffer SE, Warrington AE, Bansal R. The oligodendrocyte and its many cellular processes. Trends Cell Biol 1993;3:191-197
38. Birling MC, Roussel G, Nussbaum F, et al. Biochemical and immunohistochemical studies with specific polyclonal antibodies directed against bovine myelin/oligodendrocyte glycoprotein. Neurochem Res 1993;18:937-945
39. Brunner C, Lassmann H, Waehneldt TV, et al. Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2',3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats. J Neurochem 1989;52:296-304
40. Guggenmos J, Schubart AS, Ogg S, et al. Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis. 1. J Immunol 2004;172:661-668
41. Selter RC, Brilot F, Grummel V, et al. Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases. Neurology 2010;74:1711-1715
42. Lebar R, Lubetzki C, Vincent C, et al. The M2 autoantigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane. Clin Exp Immunol 1986;66:423-434
43. Linington C, Berger T, Perry L, et al. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur J Immunol 1993;23:1364-1372
44. Weissert R, Wallstrom E, Storch MK, et al. MHC haplotype-dependent regulation of MOG-induced EAE in rats. J Clin Invest 1998;102:1265-1273
45. Adelmann M, Wood J, Benzel I, et al. The N-Terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J Neuroimmunol 1995;63:17-27
46. Stefferl A, Brehm U, Linington C. The myelin oligodendrocyte glycoprotein (MOG): A model for antibody-mediated demyelination in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neural Transm Suppl 2000;58:123-133
47. Storch MK, Stefferl A, Brehm U, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998;8:681-694
48. Sakuma H, Kohyama K, Park IK, et al. Clinicopathological study of a myelin oligodendrocyte glycoprotein-induced demyelinating disease in LEW.1AV1 rats. Brain 2004;127:2201-2213
49. Merkler D, Ernsting T, Kerschensteiner M, et al. A new focal EAE model of cortical demyelination: Multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination. Brain 2006;129:1972-1983
50. Lucchinetti CF, Popescu BF, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011;365:2188-2197
51. Mendel I, Gur H, Kerlero De RN, et al. Experimental autoimmune encephalomyelitis induced in B6.C-H-2bm12 mice by myelin oligodendrocyte glycoprotein: Effect of MHC class II mutation on immunodominant epitope selection and fine epitope specificity of encephalitogenic T cells. J Neuroimmunol 1999;96:9-20
52. Lalive PH. Autoantibodies in inflammatory demyelinating diseases of the central nervous system. Swiss Med Wkly 2008;138:692-707
53. Slavin AJ, Soos JM, Stuve O, et al. Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity. J Clin Invest 2001;108:1133-1139
54. Eugster HP, Frei K, Kopf M, et al. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol 1998;28:2178-2187
55. Calida DM, Constantinescu C, Purev E, et al. Cutting edge: C3, a key component of complement activation, is not required for the development of myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis in mice. J Immunol 2001;166:723-726
56. Zhang GX, Yu S, Gran B, et al. T cell and antibody responses in remitting-relapsing experimental autoimmune encephalomyelitis in (C57BL/6 x SJL) F1 mice. J Neuroimmunol 2004;148:1-10
57. Urich E, Gutcher I, Prinz M, et al. Autoantibody-mediated demyelination depends on complement activation but not activatory Fc-receptors. Proc. Natl. Acad. Sci. USA 2006;103:18697-702
58. Matsushita T, Fujimoto M, Hasegawa M, et al. Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response. Am J Pathol 2006;168:812-821
59. Du C, Sriram S. Increased severity of experimental allergic encephalomyelitis in lyn-/- mice in the absence of elevated proinflammatory cytokine response in the central nervous system. J Immunol 2002;168:3105-3112
60. Bettelli E, Pagany M, Weiner HL, et al. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med 2003;197:1073-1081
61. Pollinger B, Krishnamoorthy G, Berer K, et al. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med 2009;206:1303-1316
62. Krishnamoorthy G, Lassmann H, Wekerle H, et al. Spontaneous opticospinal encephalomyelitis in a double-Transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest 2006;116:2385-2392
63. Bettelli E, Baeten D, Jager A, et al. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest 2006;116:2393-2402
64. Kerlero De RN, Brok HP, Bauer J, et al. Rhesus monkeys are highly susceptible to experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein: Characterisation of immunodominant Tand B-cell epitopes. J Neuroimmunol 2000;110:83-96
65. Brok HP, Uccelli A, Kerlero De RN, et al. Myelin/oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in common marmosets: The encephalitogenic T cell epitope pMOG24-36 is presented by a monomorphic MHC class II molecule. J Immunol 2000;165:1093-1101
66. Merkler D, Schmelting B, Czeh B, et al. Myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in the common marmoset reflects the immunopathology of pattern II multiple sclerosis lesions. Mult Scler 2006;12:369-374
67. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717
68. Lucchinetti CF, Bruck W, Rodriguez M, et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996;6:259-274
69. Storch MK, Stefferl A, Brehm U, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998;8:681-694
70. Zhou D, Srivastava R, Nessler S, et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc. Natl. Acad. Sci. USA 2006;103:19057-62
71. Brehm U, Piddlesden SJ, Gardinier MV, et al. Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG). J Neuroimmunol 1999;97:9-15
72. Bourquin C, Iglesias A, Berger T, et al. Myelin oligodendrocyte glycoprotein-DNA vaccination induces antibody-mediated autoaggression in experimental autoimmune encephalomyelitis. Eur J Immunol 2000;30:3663-3671
73. Litzenburger T, Fassler R, Bauer J, et al. B lymphocytes producing demyelinating autoantibodies: Development and function in gene-Targeted transgenic mice. J Exp Med 1998;188:169-180
74. Berger T, Reindl M. Biomarkers in multiple sclerosis: Role of antibodies. Dis Markers 2006;22:207-212
75. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003;349:139-145
76. Kuhle J, Pohl C, Mehling M, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007;356:371-378
77. Lalive PH, Menge T, Delarasse C, et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc. Natl. Acad. Sci. USA 2006;103:2280-2285
78. Menge T, Lalive PH, von Budingen HC, et al. Conformational epitopes of myelin oligodendrocyte glycoprotein are targets of potentially pathogenic antibody responses in multiple sclerosis. J Neuroinflammation 2011;8:161-173
79. Lalive PH, Hausler MG, Maurey H, et al. Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler 2011;17:297-302
80. Reindl M, Khalil M, Berger T. Antibodies as biological markers for pathophysiological processes in MS. J Neuroimmunol 2006; 180:50-62
81. Wang H, Munger KL, Reindl M, et al. Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults. Neurology 2008;71:1142-1146
82. Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 2011;8:184-192
83. Brilot F, Dale RC, Selter RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009;66:833-842
84. Di PF, Mader S, Rostasy K, et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol 2011;138:247-254
85. McLaughlin KA, Chitnis T, Newcombe J, et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009;183:4067-4076
86. O'Connor KC, McLaughlin KA, De Jager PL, et al. Self-Antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007;13:211-217
87. Probstel AK, Dornmair K, Bittner R, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 2011;77:580-588
88. Banwell B, Ghezzi A, Bar-Or A, et al. Multiple sclerosis in children: Clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 2007;6:887-902
89. Tenembaum S, Chitnis T, Ness J, et al. Acute disseminated encephalomyelitis. Neurology 2007;68:S23-36
90. Haase CG, Guggenmos J, Brehm U, et al. The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls. J Neuroimmunol 2001;114:220-225
91. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717
92. Breij EC, Brink BP, Veerhuis R, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 2008;63:16-25
93. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007;130:1089-1104
94. Franciotta D, Salvetti M, Lolli F, et al. B cells and multiple sclerosis. Lancet Neurol 2008;7:852-858
95. von Budingen HC, Harrer MD, Kuenzle S, et al. Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-specific antibodies. Eur J Immunol 2008;38:2014-2023
96. von Budingen HC, Gulati M, Kuenzle S, et al. Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce "oligoclonal bands". J Neuroimmunol 2010;218:134-139
97. Dornmair K, Meinl E, Hohlfeld R. Novel approaches for identifying target antigens of autoreactive human B and T cells. Semin Immunopathol 2009;31:467-477
98. Obermeier B, Mentele R, Malotka J, et al. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med 2008;14:688-693
99. Obermeier B, Lovato L, Mentele R, et al. Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin. J Neuroimmunol 2011;233:245-248
100. Baranzini SE, Jeong MC, Butunoi C, et al. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 1999;163:5133-5144
101. Berger T, Reindl M. Immunopathogenic and clinical relevance of antibodies against myelin oligodendrocyte glycoprotein (MOG) in Multiple Sclerosis. J Neural Transm Suppl 2000;60:351-360
102. Qin Y, Duquette P, Zhang Y, et al. Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis. Lab Invest 2003;83:1081-1088
103. Reindl M, Linington C, Brehm U, et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: A comparative study. Brain 1999;122(Pt 11):2047-2056
104. Ruprecht K, Klinker E, Dintelmann T, et al. Plasma exchange for severe optic neuritis: Treatment of 10 patients. Neurology 2004;63:1081-1083
105. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878-886
106. Miyazawa R, Hikima A, Takano Y, et al. Plasmapheresis in fulminant acute disseminated encephalomyelitis. Brain Dev 2001;23:424-426
107. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Ann Neurol 2008;63:395-400
108. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-688
109. Stuve O, Nessler S, Hartung HP, et al. Acute disseminated encephalomyelitis. Pathogenesis, diagnosis, treatment, and prognosis. Nervenarzt 2005;76:701-707
110. Cross AH, Stark JL, Lauber J, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006;180:63-70
111. Martin MP, Cravens PD, Winger R, et al. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol 2009;66:1016-1020
112. Monson NL, Cravens PD, Frohman EM, et al. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005;62:258-264
113. Keegan M, Konig F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005;366:579-582
114. Nowak RJ, Dicapua DB, Zebardast N, et al. Response of patients with refractory myasthenia gravis to rituximab: A retrospective study. Ther Adv Neurol Disord 2011;4:259-266
115. Weber MS, Prod'homme T, Patarroyo JC, et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 2010;68:369-383
116. Lehmann-Horn K, Schleich E, Hertzenberg D, et al. Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. J Neuroinflammation 2011;8:146-158
117. Matsushita T, Yanaba K, Bouaziz JD, et al. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008;118:3420-3430
118. Kap YS, van DN, Blezer E, et al. Late B cell depletion with a human anti-human CD20 IgG1kappa monoclonal antibody halts the development of experimental autoimmune encephalomyelitis in marmosets. J Immunol 2010;185:3990-4003
119. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;66:630-643
120. Uzawa A, Mori M, Hayakawa S, et al. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol 2010;17:672-676
121. Freedman MS, Bar-Or A, Oger J, et al. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology 2011;77:1551-1560